Piper Sandler Maintains Neutral on Fulgent Genetics, Raises Price Target to $25
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $19 to $25.
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and raises the price target from $19 to $25.